Iodine Status After Intake of Sushi and Seaweed Salad

Iodine Deficiency Clinical Trial

Official title:

Iodine Status at Several Time Points During 48 Hours After Intake of Sushi and Seaweed Salad- a Randomized Crossover Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05773456
• Other study ID #: 232247
• Status: Completed
• Phase: N/A
• Start date: August 10, 2021
• Est. completion date: June 15, 2022

Study information

• Verified date: January 2023
• Source: University of Bergen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Seaweed is becoming increasingly popular in the Western part of the world, especially sushi wrapped in nori and seaweed salad, also called wakame. There are limited data on the iodine content of different seaweed products in the Norwegian Food composition table. Furthermore, there is limited available research regarding in vivo bioavailability of iodine from seaweeds. The objective of this study is to assess whether iodine from a sushi meal (with nori, Porphyra spp), and a wakame salad (Undaria pinnatifida) has similar bioavailability as a potassium iodide reference supplement of similar iodine content.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: June 15, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• healthy women aged 18 to 40 years

Exclusion Criteria:

• pregnant or lactating

• known thyroid disease or thyroid autoimmunity,

• planning to conceive,

• known kidney problems or kidney disease.

• women with coeliac disease could not participate due to possible gluten exposure from the wakame salad

Related Conditions & MeSH terms

• Iodine Deficiency

Intervention

Other:
• Sushi and wakame salad
One serving of mixed sushi and wakame salad

Locations

Country	Name	City	State
Norway	University of Bergen	Bergen

Sponsors (2)

Lead Sponsor	Collaborator
University of Bergen	Institute of Marine Research

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary iodine concentration during 48 hours	Urinary iodine concentration after ingestion of the intervention/supplement during 48 hours by fixed time-intervals	48 hours
Primary	Bio-availability of iodine in the intervention/supplement	Calculation of the bio-availability of iodine in the intervention/supplement	48 hours